Výsledky vyhledávání - "Victoria E Hawkins"

Phase I trial of antigen-targeted autologous dendritic cell-based vaccine with in vivo activation of inducible CD40 for advanced prostate cancer

Autor: Mamatha Seethammagari, John McMannis, David M. Spencer, Kevin M. Slawin, Annemarie Moseley, Guru Sonpavde, Joan M C Bull, Theresa K. Dancsak, Natasha Lapteva, Victoria E Hawkins, Yu Bai, Jonathan M. Levitt

Publikováno v: Cancer Immunology, Immunotherapy. 66:1345-1357

This phase I trial reports the safety and activity of BPX101, a second-generation antigen-targeted autologous antigen presenting cell (APC) vaccine in men with metastatic castration-resistant prostate cancer (mCRPC). To manufacture BPX101, APCs colle

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5d831c0f1ddd7f2c36b29c1cc078528f
https://doi.org/10.1007/s00262-017-2027-6

Zobrazit plný text záznamu

Impact of Safety Concerns of Erythropoiesis-Stimulating Agents (ESAs) and Regulatory Changes on the Use of ESAs and Red Blood Cell (RBC) Transfusions at a Comprehensive Cancer Center

Autor: Lincy S. Lal, Rebecca Arbuckle, Xiao Zhou, Kurt C. Sizer, Saroj Vadhan-Raj, Victoria E. Hawkins, Robert S. Benjamin, Benjamin Lichtiger, Joyce Roquemore

Publikováno v: Blood. 112:1300-1300

Safety signals raised in the recent oncology clinical trials have led to various regulatory restrictions including FDA black-box warning, National Coverage Determination (NCD), and updated ASCO/ASH guidelines in 2007. The purpose of this study was to

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7a8327362926a131156e674454472fce
https://doi.org/10.1182/blood.v112.11.1300.1300

Zobrazit plný text záznamu

Characteristics of Patients Experiencing Thromboembolic Events during Treatment for Multiple Myeloma: Aspirin May Not Be Adequate Thromboprophylaxis in Patients with Multiple Risk Factors

Autor: Sheeba K. Thomas, Donna M. Weber, Raymond Alexanian, Victoria E. Hawkins, Jennifer A. Wright, Michael Wang, Saroj Vadhan-Raj

Publikováno v: Blood. 110:1882-1882

Patients (pts) with multiple myeloma (MM) have a high risk of venous thromboembolism (VTE) due to features of the disease or treatment, such as thalidomide (Thal), Lenalidomide (Len), steroids, and certain chemotherapeutic agents. Based on evidence s

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::97e1e32cbf7eb1f713d587b316a2e6ee
https://doi.org/10.1182/blood.v110.11.1882.1882

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání